Amgen Share Price Suggests $90 Billion Upside Gap Amid Overvaluation Concerns

Amgen (AMGN) has seen its share price rise significantly after beating Wall Street expectations in its second quarter report and raising full year revenue and earnings guidance. The company cited broad-based, volume-driven product strength for the increase.

The stock's 90-day return is 17.79% and its one-year total shareholder return is 33.88%, indicating a strong long-term picture for patient investors. Amgen now sits above the average analyst target but screens at an intrinsic discount of around 8.3%.

This discrepancy has led to questions about whether the market is being too cautious regarding data, regulation, and cyber breaches or not cautious enough. Analysts estimate that Amgen's fair value is around $359.98, which implies it is overvalued by approximately 8.3%. However, a discounted cash flow model suggests that the company's future cash flow value is $667.88, indicating a large upside gap.

Investors should be cautious and review the underlying data before making any decisions. It may also be worth considering other healthcare stocks with growth potential.